We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Disposable Device Developed for Infectious Diseases

By LabMedica International staff writers
Posted on 22 Aug 2013
An easy-to-use device that can detect a wide range of diseases in less than an hour based on color-changing paper is under development. More...


An instrument-free, paper-based, fully disposable device is being created for use in remote areas where access to medical diagnostic equipment is limited.

Scientists from the University of Washington (Seattle, WA, USA) have teamed up with those from General Electric Global Research (GE; Niskayuna, NY, USA) to develop the device. The medical instument will be about the size of a pack of playing cards, and can detect infectious disease by way of a simple nasal swab, in less than an hour. As part of this program, GE scientists will be developing next-generation paper and membrane materials, while also utilizing a suite of commercial papers and membranes, including Whatman Nucleic Acid and Protein Sample Preparation FTA cards (Piscataway, NJ, USA).

The first disease the scientists will target is methicillin-resistant Staphylococcus aureus (MRSA), a drug-resistant bacterium responsible for hard-to treat infections. MRSA is especially problematic in institutional settings, like hospitals prisons, and military bases, where people generally live in close quarters. Fast diagnosis is the key because MRSA infections can worsen rapidly, and in less than a week, take hold in human tissue and become very difficult to treat.

David Moore, PhD, the manager of the Membrane and Separation Technologies Laboratory, at GE Global Research, said, “The team is excited about this effort and the difference it could make. There's a strong desire to see the technology commercialized and used at clinics, hospitals, and the military health system, and eventually in the field and at home. We live in an on-demand world, where news and information is instantaneous. We've asked why the same can't be done for diagnosing infectious diseases where early detection is so critical to positive patient outcomes.”

Related Links:
University of Washington
General Electric Global Research
Whatman


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Hematology Consumables
Bioblood Devices
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings support integrating high-performing plasma p-tau217 assays into Alzheimer’s diagnostic workflows, provided that platform-specific calibration and standardized testing protocols are in place. (Image Credit: Adobe Stock)

Head-to-Head Study Compares Blood Tests for Early Alzheimer’s Disease Detection

Accurate, scalable diagnostics are becoming increasingly important as disease-modifying therapies reshape Alzheimer’s disease care, yet many patients still rely on invasive cerebrospinal fluid sampling... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.